Nexera Pharma has received a USD 10 million milestone from the collaboration with AbbVie and holds rights to up to USD 1.2 billion in milestones and royalties.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4565","jir_company_name":"Nexera Pharma Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-04-20","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4565-20260420-01.pdf","jir_short_summary":"Nexera Pharma has received a USD 10 million milestone from the collaboration with AbbVie and holds rights to up to USD 1.2 billion in milestones and royalties.","jir_summary":"### Progress in Drug Discovery Collaboration and Milestone Receipt\nNexera Pharma Inc. has achieved its third significant milestone during the research phase within the multi-target drug discovery collaboration focused on neurological diseases with AbbVie, receiving USD 10 million (approx. JPY 1,595 million). This milestone is expected to be mostly recognized as revenue in 2026. The collaboration was established in 2022 and leverages Nexera Pharma's proprietary NxWave\u2122 platform. The company holds rights to milestones totaling up to USD 1.2 billion and tiered royalties based on sales, demonstrating steady progress in the pipeline.\n\n### Outlook and Impact on Performance\nThe impact of this matter on the consolidated financial results for the fiscal year ending December 2026 has already been factored into the earnings guidance disclosed on February 13, 2026. Christopher Cargill, Representative Executive Officer and CEO, stated that the collaboration's outcomes contribute to expanding the pipeline's value, and the company will continue focusing on creating new therapeutic candidates addressing unmet medical needs in the neurological disease field.","jir_financial_highlights":"Milestone Received Amount: USD 10 million (approx. JPY 1,595 million) (Third milestone achieved following those in 2025)\nMaximum Total Milestones: Up to USD 1.2 billion (approx. JPY 191.4 billion) (Unknown)\nInitial Development Milestone Rights: Up to USD 40 million (approx. JPY 6,380 million) (Unknown)","jir_category":"","jir_hashtags":"#NexeraPharma, #DrugDiscoveryCollaboration, #Milestone, #JapaneseStocks","jir_key_figures":"Milestone Received Amount: USD 10 million (approx. JPY 1,595 million)\nMaximum Total Milestones: USD 1.2 billion (approx. JPY 191.4 billion)\nInitial Development Milestone Rights: Up to USD 40 million (approx. JPY 6,380 million)","jir_meta_title":"[Nexera Pharma] Received USD 10 Million Milestone in Drug Discovery Collaboration with AbbVie | April 2026","jir_meta_description":"Nexera Pharma announced receiving a USD 10 million milestone from its drug discovery collaboration targeting neurological diseases with AbbVie and holds rights to up to USD 1.2 billion in milestones and royalties.","jir_og_title":"[Nexera Pharma] Received USD 10 Million Milestone in Drug Discovery Collaboration with AbbVie","jir_og_description":"Nexera Pharma has achieved a significant milestone in its collaboration with AbbVie and received USD 10 million.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16880,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-41392","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n